Evidence map›Paper›PMID 38329496›Full record

ArticleEuropean biophysics journal : EBJ2024

BASIS: BioAnalysis SEDFIT integrated software for cGMP analysis of SV-AUC data.

Alexander E Yarawsky, Erik S Gough, Valeria Zai-Rose, Natalya I Figueroa, Hazel M Cunningham, John W Burgner, Michael T DeLion, Lake N Paul

Abstract read
PubMed Publisher
In one paragraph

Article in European biophysics journal : EBJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexander E Yarawsky *BioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA.
Erik S Gough *BioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA.
Valeria Zai-RoseBioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA.
Natalya I FigueroaBioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA.
Hazel M CunninghamBioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA.
John W BurgnerBioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA.
Michael T DeLionBioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA.
Lake N PaulBioAnalysis, LLC, 3401 I Street Suite 206, Philadelphia, PA, 19134, USA. lpaul@bioanalysisllc.com.ORCID http://orcid.org/0000-0001-8500-8367

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sedimentation velocity analytical ultracentrifugation (SV-AUC) has long been an important method for characterization of antibody therapeutics. Recently, SV-AUC has experienced a wave of new interest and usage from the gene and cell therapy industry, where SV-AUC has proven itself to be the "gold standard" analytical approach for determining capsid loading ratios for adeno-associated virus (AAV) and other viral vectors. While other more common approaches have existed in the realm of cGMP-compliant techniques for years, SV-AUC has long been used strictly for characterization, but not for release testing. This manuscript describes the challenges faced in bringing SV-AUC to a cGMP environment and describes a new program, "BASIS", which allows for 21 CFR Part 11-compliant data handling and data analysis using the well-known and frequently cited SEDFIT analysis software.

Indexed as

AntibodiesSoftwareArea Under CurveUltracentrifugationAntibodies21 CFR Part 11Adeno-associated viral vectorsAntibodycGMPSEDFITTrace aggregate

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.